Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Cash & Equivalents data on file, last reported at $51.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $51.8 million, down 29.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.8 million (down 29.72% YoY), and the FY2025 annual result was $52.3 million, down 87.85% from the prior year.
• Cash & Equivalents declined to $51.8 million in Q1 2026 per JANX's latest filing, from $52.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $430.6 million in Q4 2024 and troughed at $14.7 million in Q2 2024.
• A 5-year average of $76.1 million and a median of $51.8 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 2142.15% in 2024, then tumbled 87.85% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $51.4 million in 2022, then tumbled by 62.66% to $19.2 million in 2023, then jumped by 2142.15% to $430.6 million in 2024, then plunged by 87.85% to $52.3 million in 2025, then fell by 0.97% to $51.8 million in 2026.
• Business Quant data shows JANX's Cash & Equivalents at $51.8 million in Q1 2026, $52.3 million in Q4 2025, and $48.4 million in Q3 2025.